Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
06:40am, Tuesday, 28'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)
05:30pm, Monday, 27'th Oct 2025
NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Why Avidity Biosciences Stock Blasted 42% Higher Today
05:12pm, Monday, 27'th Oct 2025
It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space.
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
02:52pm, Monday, 27'th Oct 2025
Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.
Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday
12:31pm, Monday, 27'th Oct 2025
Shares of Avidity Biosciences (RNA) soared more than 40% Monday after Novartis (NVS) agreed to buy the U.S. biopharmaceutical firm for about $12 billion in cash to expand its RNA-based disease-fightin
Is it too late to buy Avidity stock after Novartis deal?
10:22am, Monday, 27'th Oct 2025
Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announc
Novartis to acquire Avidity Biosciences in $12B deal
09:13am, Monday, 27'th Oct 2025
Novartis AG (ADR) (NYSE:NVS) announced it will acquire San Diego-based biopharmaceutical firm Avidity Biosciences (NASDAQ:RNA), which is developing RNA therapeutics for genetic neuromuscular diseases,
5 Things to Know Before the Stock Market Opens
09:05am, Monday, 27'th Oct 2025
Stock futures are pointing to a sharply higher open this morning after major indexes closed last week at record highs; investor sentiment is getting a boost after President Donald Trump said he was op
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk
08:16am, Monday, 27'th Oct 2025
President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences.
Wall Street Breakfast Podcast: Novartis Puts $12B On The Table
06:54am, Monday, 27'th Oct 2025
Avidity Biosciences (RNA) surges 42% premarket after Novartis agrees to acquire the company for $12 billion, paying $72 per share in cash. The RNA deal signals renewed Big Pharma interest in RNA thera
Novartis shares slip, Avidity soars after $12 billion biotech deal
06:29am, Monday, 27'th Oct 2025
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CE
Novartis Agrees $12 Billion Biotech Deal for Avidity
04:59am, Monday, 27'th Oct 2025
Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker's biggest acquisition in more than a decade and adding several potential blockbust
RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS
06:36pm, Sunday, 26'th Oct 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your righ
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
05:33pm, Sunday, 26'th Oct 2025
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
